This study examined effects of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor cerivastatin on human saphenous vein (SV), endothelial cells (EC) and smooth muscle cells (SMC). BACKGROUND Venous bypass graft failure involves EC dysfunction and SMC proliferation. Substances that improve EC function and inhibit SMC proliferation would be of clinical relevance.
Coronary bypass grafting using autologous internal mammary arteries and saphenous veins (SVs) is routinely used for treatment of patients with multivessel coronary artery disease. The patency rates of the arterial and venous grafts are, however, quite different. Occlusions are rare in the internal mammary artery, whereas they occur more frequently in the vein (1, 2) . Occlusion of the venous grafts is the major cause of recurrent ischemia in patients after coronary bypass surgery. Because of a shortage of arterial graft material and the relative ease of harvesting long vascular segments, SVs are still widely used. Considering the large number of patients who received venous bypass grafts in the last decades, the increasing incidence of venous bypass graft disease made the development of approaches to treat such patients an important therapeutic challenge.
Venous bypass graft failure is primarily related to biological properties of endothelial cells (ECs) and smooth muscle cells (SMCs) (3, 4) . The endothelium of the SV releases much less nitric oxide (NO) compared with that of the internal mammary artery (3, 4) . Nitric oxide is produced from L-arginine via endothelial nitric oxide synthase (eNOS) and is a potent vasodilator, platelet inhibitor and anti-proliferative agent (5) . In the arterial circulation, the venous endothelium is unable to prevent platelet-vessel wall interaction, which favors thrombus formation and vascular occlusion (6) . Furthermore, SMCs from SVs grow excessively in response to several growth factors such as plateletderived growth factor (PDGF) and thrombin (4, 7, 8) . This may contribute to the lower long-term patency rate of venous grafts.
Although mechanisms of cell growth regulation have not yet been fully understood, recent evidence suggests that signal transduction molecules such as MAPK, PI-3K and p70 S6K , which are activated by tyrosine kinase receptors such as PDGF receptors, are important for cell cycle progression (9 -11) . Cell cycle progression is positively regulated by the orderly activation of cyclin-dependent kinases (Cdks) and negatively regulated by several Cdk inhibitors known as CKIs (12) (13) (14) . p27
Kip1 is most likely involved in cell cycle control in human SV SMC (8) . Cyclin D-Cdk4/Cdk6 regulates G1 progression, and cyclin E-Cdk2 is essential for G1/S transition by phosphorylating and inactivating the tumor suppressor gene product, pRB (12) (13) (14) , which causes release and activation of E2F transcription factor and in turn regulates several proteins required for cell proliferation (14) .
Lipid-lowering therapy with 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase inhibitors strikingly decreases cardiovascular morbidity and mortality (15) (16) (17) (18) . The effects of those agents have been attributed to inhibition of cholesterol synthesis and lowering of low-density lipoprotein plasma levels. However, not all the clinical benefits of the agents can be explained by their lipid-lowering effects (19) . Moreover, whether all the effects of statins could be explained by inhibition of HMG-CoA reductase is not clear. A recent study indicates that HMG-CoA reductase inhibitors could possess biological effects independent of HMG-CoA reductase (20) .
In the clinical setting no optimal therapy for venous bypass graft disease is available (21) . This may be related, at least in part, to the fact that antiproliferative drugs may not be able to improve endothelial function and at the same time inhibit SMC proliferation. In this study, we hypothesized that the new HMG-CoA reductase inhibitor cerivastatin could meet these criteria in human SVs and therefore may have the important clinical impact of improving venous bypass graft function. Moreover, we also investigated whether cerivastatin affects EC and SMC function in human SVs solely by the classic mechanism (i.e., inhibition of HMG-CoA reductase).
METHODS

Chemicals and materials.
Bovine serum albumin (BSA, 7.5%), monoclonal antibody against smooth muscle ␣-actin, and all chemicals for immunoblotting were from Sigma (Buchs, Switzerland); recombinant human PDGF-BB was from (R&D Systems GmbH, Wiesbaden, Germany); all tissue culture materials were from Gibco (Basel, Switzerland); 3 H-methyl-thymidine was from Amersham (Zürich, Switzerland); trichloroacetic acid was from Fluka (Buchs, Switzerland); rabbit polyclonal anti-human p42 mapk (C14), p27 Kip1 (C19), and Cdk2 (M2) were from Santa Cruz Biotechnol (Basel, Switzerland); mouse monoclonal antibody against human p21
Cip1 (Clone EA10) was from Calbiochem (JURO Supply AG, Lucerne, Switzerland); mouse monoclonal antibody against human eNOS (N30020) was from Transduction Laboratories (Basel, Switzerland); rabbit polyclonal anti-human phospho-pRB (Ser807/811) was from New England BioLabs (Schwalbach/ Taunus, Germany); mevalonate was from Sigma (Buchs, Switzerland); and cerivastatin was kindly supplied by Bayer AG (Leverkusen, Germany). Cultivation of ECs and SMCs. Endothelial cells were isolated from human SVs as described (4) . Briefly, fresh blood vessels were harvested in a cold sterile RPMI-1640 medium with antibiotics (100 U/ml penicillin and 100 g/ml streptomycin). The vessels cleaned of connective tissue and adventitia were incubated with collagenase type II 75 U/ml for 15 min in phosphate-buffered saline (PBS). Cell pellets were then collected by centrifugation at 1,000 rpm for 10 min and seeded in culture dishes coated with 25 g/ml human fibronectin and cultured in RPMI-1640 supplemented with 20 mmol/liter L-glutamine, HEPES buffer solution, 100 U/ml penicillin and 100 g/ml streptomycin, 50 g/ml endothelial cell growth supplement, 25 g/ml heparin and 20% fetal calf serum (FCS). The day after, cells were washed with the medium to eliminate blood cell contamination. Endothelial cells were characterized by typical cobblestone and nonoverlapping appearance and indirect immunofluorescence staining using specific antibodies against von Willebrand factor. Cells of third and fourth passage were used.
Vascular SMC were cultivated from SVs obtained from patients undergoing coronary bypass surgery using explant technique as previously described (4, 8) . Briefly, the cells were cultured in Dulbecco's modified eagle medium containing 20% FCS supplemented with 20 mmol/liter L-glutamine and HEPES buffer solution, 100 U/ml penicillin and 100 g/ml streptomycin in a humidified atmosphere (37°C; 95% air/5% CO 2 ). Culture medium was replaced every three days. Cells were passaged by trypsination (0.01% EDTA). Experiments were performed between passages five to eight. The SMC were characterized by typical morphological pattern (multilayer sheets and "hills and valleys") and indirect immunofluorescence staining using specific mouse monoclonal antibodies against human SMC ␣-actin (Sigma). The eNOS expression. Confluent ECs were rendered quiescent for 24 h by changing the medium to RPMI-1640 with the same ingredients as described above except that EC growth supplement and heparin were avoided and only 0.5% FCS was added. The cells were then treated with cerivas- .5% glycerol, 0.0075% bromophenol blue), followed by heating at 95°C for 3 min and then subjected to 8% SDS-PAGE gel for electrophoresis. The proteins were then transferred onto Immobilon TM -P filter papers (Millipore AG, Volketswil, Switzerland) with a semi-dry transfer unit (Hoefer Scientific, Switzerland). The membranes were then blocked by using 5% skim milk in PBS-Tween buffer (0.1% Tween 20; pH ϭ 7.5) for 1 h and incubated with the antibody against human eNOS (1:600). The immunoreactive bands were detected by an enhanced chemiluminescence system (Amersham, Zürich, Switzerland). Measurement of NO release. In parallel experiments the cells treated with cerivastatin and mevalonate as described above were used for measurement of NO release by porphyrin microsensor (22) . Amperometric mode detection was used at a constant potential equal to the peak potential for NO oxidation of the electrode. The NO concentration was determined from the measured current by means of a calibration curve with NO standards. Standard NO solutions (1.8 mmol/liter) were prepared from aequeous solutions saturated with pure gaseous NO. Immediately before NO measurements, the active tip of the L-shaped porphyrinic NO microsensor was placed directly on the surface of the EC monolayer. The monolayer had been washed three times with PBS, pre-warmed to 37°C, immediately before the measurements. For maximal stimulation of eNOS, Ca 2ϩ ionophore A23187 was injected into the cell culture dish to yield a final concentration of 10 Ϫ6 mmol/liter. In some experiments, EC monolayers were pre-incubated with L-NAME (10 Ϫ4 mmol/liter) for 15 min before NO measurements. Only a very marginal signal could be recorded under this condition, and this was subtracted during the calculation. 3 H-Thymidine. The SV SMCs were seeded on 12-well plates at a density of 2 ϫ 10 4 /well and exposed to PDGF-BB in the presence or absence of cerivastatin or cerivastatin plus mevalonate. The DNA synthesis was measured by 3 H-thymidine (1 Ci/ml; 70 to 85 Ci/mol) incorporation after 24 h as described (4, 8) . Activation of protein kinase. Activation of MAPK as well as p70 S6K were analyzed by mobility shift of the kinases on Western blots as described (4, 8) . The cells were pre-treated with different substances tested, then stimulated with PDGF-BB (10 ng/ml) for 10 min and harvested in the extraction buffer as previously described (8) . Cell lysates above 20 g were treated with 5xLaemmli's SDS-PAGE sample buffer and subjected to 10% SDS-PAGE gel for electrophoresis. Western blot was performed by using specific antibodies. Cell cycle regulatory proteins. The cells were stimulated with PDGF-BB (10 ng/ml) in the presence or absence of cerivastatin or cerivastatin plus mevalonate for 24 h, and then harvested with extraction buffer as described (8) . Regulation of CKIs (p21 Cip1 and p27 Kip1 ), Cdk2 and pRb phosphorylation by PDGF-BB was analyzed by immunoblotting as described above; 12% SDS-PAGE was used for analysis of p21
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Cip1 and p27 kip1 ; Cdk2 and 8% SDS-PAGE were used for detection of phosphorylation of pRb. Statistics. Data are means Ϯ SEM. The 3 H-thymidine incorporation and MAPK activity were expressed as percent increase above control. In all experiments, n equals the number of patients from which vessels were obtained. The Student t test for paired observations and analysis of variance followed by the Scheffe test for repeated measurements were used. A two-tailed p value smaller than 0.05 was considered significant.
RESULTS
Effects of cerivastatin on eNOS.
In cultured human SV-EC, treatment of the cells with cerivastatin (10 Ϫ9 to 10 Ϫ6 mol/liter; 24 h) up-regulated the eNOS protein level in a concentration-dependent manner (Fig. 1, top panel) . Densitometry showed that the increase in eNOS protein level reached about two-fold (Fig. 1, lower panel, n ϭ 3) . This up-regulation of eNOS expression by cerivastatin (10 Ϫ6 mol/liter) was fully reversed by mevalonate (2 ϫ 10 4 mol/liter) ( Fig. 2A, B) . Accordingly, NO production stimulated by Ca 2ϩ ionophore (10 Ϫ6 mol/liter) in the cells treated with cerivastatin (10 Ϫ6 mol/liter) for 24 h was also markedly increased (from 393 Ϯ 55 nmol/liter to 840 Ϯ 
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Cerivastatin and Human Venous Bypass Grafts 42% nmol/liter, n ϭ 3, p Ͻ 0.01) as measured by the porphyrinic microsensor (Fig. 2C ). Similar to eNOS protein expression, the enhanced NO release by cerivastatin was also fully reversed by treatment of the cells with mevalonate (2 ϫ 10 4 mol/liter; Fig. 2C , 372 Ϯ 78 nmol/ liter, p Ͻ 0.01 vs. cerivastatin-treated cells), whereas mevalonate alone had no effects. Effects of cerivastatin on SMC proliferation. In cultured human SV SMC, the growth factor PDGF-BB (5 ng/ml) markedly enhanced 3 H-thymidine incorporation (298 Ϯ 23% above control, n ϭ 4), which was concentrationdependently inhibited by cerivastatin (data not shown). The inhibitory effects of cerivastatin (10 Ϫ6 mol/liter; 164 Ϯ 11%) was only partially abrogated by co-incubation of the cells with mevalonate (2 ϫ 10 4 mol/liter; 211 Ϯ 13%, Fig.  3 ; n ϭ 4, p Ͻ 0.05 vs. cerivastatin plus PDGF). Mevalonate alone had no effects on 3 H-thymidine incorporation. Effects of cerivastatin on MAPK and p70 S6K activation. After stimulation of SMC with PDGF-BB (10 ng/ml, 10 min) both p42 mapk and p70 S6K were activated, as demonstrated by a slower mobility of the activated (phosphorylated) kinase on Western blots (Fig. 4) . Cerivastatin (10 Ϫ6 mol/liter) did not exhibit inhibitory effects on either p42 mapk or p70 S6K activation in response to PDGF-BB (Fig. 4) . By contrast, activation of p42 mapk was specifically inhibited by PD98059 (5 ϫ 10 Ϫ5 mol/liter), a specific MAPK kinase (MEK) inhibitor. The p70 S6K activation stimulated by PDGF-BB (10 ng/ml) was prevented by rapamycin (10 Ϫ5 mol/liter), a specific inhibitor of p70 S6K , and also by wortmannin (10 Ϫ5 mol/liter), a specific inhibitor of PI3-K (Fig. 4) . Effects of cerivastatin on cell cycle regulators. Western blotting demonstrated that stimulation of the SV SMC with PDGF-BB (10 ng/ml) for 24 h induced activation of Cdk2 accompanied by an increase in its electrophoretic : In cultured human saphenous vein, SMC PDGF-BB (10 ng/ml, 10 min) markedly stimulated (or phosphorylated) p42 mapk as demonstrated by the slower mobility of the enzyme on Western blots. The activation of p42 mapk was not inhibited by cerivastatin (10 Ϫ6 mol/liter), but was markedly reduced by the specific inhibitor of MAPK kinase (MEK), PD98059 (5 ϫ 10 Ϫ5 mol/liter), while the PI3K inhibitor (wortmannin, 10 Ϫ5 mol/liter) or the p70 S6K inhibitor (rapamycin, 10 Ϫ5 mol/liter) had no effects on p42 mapk activation. The same blots were used for analysis of p70 S6K . PDGF-BB stimulated p70 S6K activation (or phosphorylation) as demonstrated by the slower mobility of the enzyme on Western blots, which was not influenced by cerivastatin or by PD98095, the specific inhibitor of MEK. In contrast, activation of p70 S6K was completely prevented by wortmannin or rapamycin. The results were repeated with three independent experiments. mobility on SDS-PAGE (Fig. 5) due to Cdk2 phosphorylation on Thr160 (23), down-regulation of p27
Kip1 and phosphorylation of pRb. In contrast, p21
Cip1 was not down-regulated by PDGF-BB (Fig. 5) . Cerivastatin (10 Ϫ6 mol/liter) inhibited PDGF-induced activation of Cdk2 and pRb phosphorylation but had no significant effects on the down-regulation of p27 Kip1 (Fig. 5 ). These effects of cerivastatin on Cdk2 and Rb were almost fully reversed by mevalonate (2 ϫ 10 Ϫ4 mol/liter).
DISCUSSION
The present finding. The major findings of the present study are that in human SV the HMG-CoA reductase inhibitor cerivastatin enhances eNOS protein level and NO release by the classic mechanism (i.e., inhibition of HMGCoA reductase) in EC, whereas inhibition of HMG-CoA reductase only partially contributes to the inhibitory effects of cerivastatin on SMC growth in response to PDGF. Mechanisms other than inhibition of p42 mapk , PI-3K/ p70 S6K or Cdk2 are involved. Effect of cerivastatin on SV EC. Clinical trials demonstrated that HMG-CoA reductase inhibitors markedly reduce mortality and morbidity in patients with coronary artery disease or stroke (15) (16) (17) 24) . There is increasing evidence that HMG-CoA reductase inhibitors exhibit several beneficial effects via non-lipid-dependent mechanisms (19) . In line with the experiments with simvastatin and lovastatin (18, (25) (26) (27) , the present study demonstrated that cerivastatin enhanced eNOS protein expression and NO release by Ca 2ϩ ionophore in the same cells. These effects of cerivastatin were fully abrogated by the HMG-CoA product mevalonate, indicating that cerivastatin up-regulates eNOS protein level via inhibition of HMG-CoA reductase in the human SV EC. By contrast, inhibition of HMGCoA reductase in bovine aortic ECs does not increase eNOS expression (28) . The mechanism for the discrepancy is not clear. It might be due to the different cell types used. The molecular mechanism of increase in eNOS expression by statins in the human SV EC is due to inhibition of Rho GTPase, whose activation is dependent on prenylation induced by mevalonate metabolites and negatively regulates stability of eNOS mRNA. (26, 27) . Our results provide evidence that the HMG-CoA reductase inhibitors help to adapt endothelial function in the human SV to the arterial circulation where higher amounts of NO production are required than the venous side. Effect of cerivastatin on SV SMCs. In addition to endothelial dysfunction, an enhanced vascular SMC growth also importantly contributes to human venous bypass graft failure (6 -8) . Our previous study demonstrated that the growth factor PDGF released from aggregating platelets at the site of vascular injury is an important mediator of SV SMC growth (8) . Further evidence demonstrated that p42/44 mapk , PI-3K and p70 S6K are important signaling molecules for cell growth (9 -11) . The present study demonstrated that cerivastatin is a potent inhibitor of SMC growth of the SV. However, the inhibitory effect of cerivastatin on the SMC growth is only partially reversed by the HMG-CoA product mevalonate, indicating that, unlike in the ECs, inhibition of the HMG-CoA/mevalonate pathway only partially contributes to the inhibitory effect of the drug on SMC growth. Other studies showed that HMGCoA reductase inhibitors prevent cell growth by blocking Rho GTPase via inhibition of the protein prenylation induced by mevalonate metabolites (29 -31) . The results from the present study with mevalonate suggest that this mechanism is only partially involved in cell growth. We further analyzed whether cerivastatin could interfere with other signal transduction mechanisms such as p42 mapk and p70 S6K . Interestingly, our results showed that cerivastatin did not influence p42 mapk or p70 S6K activation. This suggests that cerivastatin inhibits SMC growth via mechanisms other than p42 mapk and p70 S6K . The exact mechanisms remain to be explored.
The cell growth is positively regulated by the orderly activation of Cdks and negatively regulated by several Cdk inhibitors (12) (13) (14) . In the present study we demonstrated that the growth factor PDGF activated Cdk2 and phosphorylated Rb, both of which were inhibited by cerivastatin. These effects of cerivastatin were almost fully reversed by mevalonate, indicating that cerivastatin prevented PDGFinduced Cdk2 activation and Rb phosphorylation via the classic mechanism (i.e., inhibition of HMG CoA reductase). Of note, the rescuing effects of mevalonate on Cdk2 and Rb were not fully correlated with the reversal of 3 H-thymidine incorporation by the substance. Only about one-third of the inhibition of 3 H-thymidine incorporation by cerivastatin was reversed by mevalonate. This indicates that inhibition of HMG-CoA reductase linked to Cdk2 blockade is only one mechanism of the drug-induced growth arrest of SMCs. It is possible that other cell-cycle regulatory proteins are still inhibited by cerivastatin independent on HMG-CoA/mevalonate pathway. This issue needs additional investigation.
Furthermore, results of the present study showed that p27 Kip1 , but not p21
Cip1
, was down-regulated by PDGF. 
